BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2025 9:41:58 AM | Browse: 255 | Download: 129
 |
Received |
|
2025-05-16 10:27 |
|
Peer-Review Started |
|
2025-05-20 00:11 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-06-04 03:30 |
|
Revised |
|
2025-06-16 08:53 |
|
Second Decision |
|
2025-08-08 09:20 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-08-15 10:46 |
|
Articles in Press |
|
2025-08-15 10:46 |
|
Publication Fee Transferred |
|
2025-06-20 10:15 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-09-03 01:03 |
|
Publish the Manuscript Online |
|
2025-09-11 09:41 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Basic Study |
| Article Title |
Farrerol ameliorates diabetic cardiomyopathy by inhibiting ferroptosis via miR-29b-3p/SIRT1 signaling pathway in endothelial cells
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yan Guo, Xin-Rou Yu, Hao-Di Gu, Yu-Jie Wang, Zhen-Gang Yang, Ju-Fang Chi, Liu-Ping Zhang and Hui Lin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Medical Health Science and Technology Project of Zhejiang Provincial |
2025KY1721 and 2022KY1292 |
| Science and Technology Projects of Shaoxing City |
2022KY104 |
|
| Corresponding Author |
Hui Lin, MD, PhD, Department of Cardiology, The Affiliated Lihuili Hospital of Ningbo University, No. 57 Xingning Road, Yinzhou District, Ningbo 315211, Zhejiang Province, China. 122525790@qq.com |
| Key Words |
Diabetic cardiomyopathy; Microvascular dysfunction; Farrerol; MiR-29b-3p; SIRT1 |
| Core Tip |
This study was the first to identify the miR-29b-3p/SIRT1 axis as a critical mechanism underlying the attenuation of endothelial ferroptosis and microvascular dysfunction of farrerol (FA) in diabetic cardiomyopathy (DCM). These results highlight the translational potential of targeting miR-29b-3p or administering FA for the treatment of DCM. |
| Publish Date |
2025-09-11 09:41 |
| Citation |
<p>Guo Y, Yu XR, Gu HD, Wang YJ, Yang ZG, Chi JF, Zhang LP, Lin H. Farrerol ameliorates diabetic cardiomyopathy by inhibiting ferroptosis via miR-29b-3p/SIRT1 signaling pathway in endothelial cells. <i>World J Diabetes</i> 2025; 16(9): 109553</p> |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i9/109553.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i9.109553 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
